Calcium antagonists "some agents lower blood pressure and still put the heart at risk"?
The 1,4 dihydropyridine calcium antagonists have several properties that theoretically make them attractive for treatment of hypertension and prevention as well as management of coronary artery disease (CAD). However, some of them appear to have actions that are detrimental for outcome. This brief review will first address the different subclasses of dihydropyridines, then outline differences between these subclasses which may impact on outcome in CAD and hypertension, and the last part will review present evidence for differences in cardiac outcome.
Leenen
F H
FH
Hypertension Unit, University of Ottawa Heart Institute, Ontario, Canada.
D000787:Angina Pectoris / Q000188:drug therapy / Q000517:prevention & control; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002118:Calcium / Q000037:antagonists & inhibitors*; D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy; D004095:Dihydropyridines / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy; D012307:Risk Factors
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D002118:Calcium